Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. (21st April 2023)

• Record Type: Journal Article
• Authors: Emdin, Michele; Morfino, Paolo; Crosta, Lucia; Aimo, Alberto; Vergaro, Giuseppe; Castiglione, Vincenzo
• Is Part Of: European heart journal supplements. Volume 25(2023)Supplement B
• Page Start: B79
• Page End: B84
• Publication Date: 2023-04-21
• Subjects: Cardiac amyloidosis -- Monoclonal antibodies -- Light chains -- Transthyretin; Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suad079
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Cardiac amyloidosis (CA) is an infiltrative disease caused by progressive deposition of amyloid fibres in the heart. The most common forms include immunoglobulin light-chain and transthyretin amyloidosis. Current therapies for CA either stabilize or block the production of amyloidogenic precursors, preventing further amyloid deposition. This approach, while reducing cell damage and disease progression, does not target pre-existing amyloid deposits. Conversely, amyloid removal might stimulate functional recovery of the affected organ, thus improving quality of life and survival. A therapeutic strategy based on monoclonal antibodies capable of selectively binding amyloid deposits and inducing their removal has recently been tested in various clinical trial, with promising results, and could represent a key treatment for CA in the near future.